Other promising therapies are in study or already in use, such as PD-1/PDL-1 pathway blocking agents, multi-targeted tyrosine kinase inhibitors, MCPyV-related immunotherapy and AURKA inhibitors, potentially useful in MCPyV-negative MCC, among others [9,10,35,36]. This evidence concerns the gene CD274 and Merkel cell skin cancer.